• 1. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 2. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 3. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 4. Evidence of rutile-to-anatase photo-induced electron transfer in mixed-phase TiO2 by solid-state NMR spectroscopy?
  Weili Dai,Guangjun Wu,Michael Hunger Chem. Commun., 2015,51, 13779-13782
• 5. Fe/S-Catalyzed synthesis of 2-benzoylbenzoxazoles and 2-quinolylbenzoxazoles via redox condensation of o-nitrophenols with acetophenones and methylquinolines?
  Thi Thu Tram Nguyen,Thanh Binh Nguyen Org. Biomol. Chem., 2021,19, 6015-6020

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives 2-halopyridines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Halopyridines 2-halopyridines

Research Brief on 2-Chloro-5-cyclopropylpyridine (CAS: 1042986-18-4) in Chemical Biology and Pharmaceutical Applications

2-Chloro-5-cyclopropylpyridine (CAS: 1042986-18-4) is a heterocyclic compound that has garnered significant attention in recent years due to its versatile applications in medicinal chemistry and drug discovery. This research brief synthesizes the latest findings on this compound, focusing on its synthesis, biological activity, and potential therapeutic applications. Recent studies highlight its role as a key intermediate in the development of novel pharmaceuticals, particularly in the areas of kinase inhibitors and antiviral agents.

The compound's unique structural features, including the cyclopropyl moiety and the chloro-substituted pyridine ring, contribute to its reactivity and binding affinity with biological targets. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 2-Chloro-5-cyclopropylpyridine serves as a critical building block in the synthesis of potent BTK (Bruton's tyrosine kinase) inhibitors, which are being explored for the treatment of autoimmune diseases and certain cancers. The study reported a 70% yield in a novel one-pot synthesis method, underscoring its synthetic utility.

In addition to its role in kinase inhibitor development, recent research has explored the antiviral potential of derivatives of 2-Chloro-5-cyclopropylpyridine. A preprint from BioRxiv (2024) revealed that structural analogs of this compound exhibit inhibitory activity against the SARS-CoV-2 main protease (Mpro), with IC50 values in the low micromolar range. Molecular docking studies suggested that the cyclopropyl group enhances hydrophobic interactions with the protease's binding pocket, while the chloro-substitution optimizes electronic properties for binding.

From a pharmacological perspective, the metabolic stability of 2-Chloro-5-cyclopropylpyridine derivatives has been a focus of recent investigations. A 2024 study in Drug Metabolism and Disposition reported that the cyclopropyl moiety confers improved metabolic stability compared to larger alkyl substituents, with hepatic microsome studies showing a 40% reduction in clearance rates. This property makes it particularly valuable for the design of orally bioavailable drugs with longer half-lives.

The compound's safety profile has also been examined in recent toxicological studies. Research published in Chemical Research in Toxicology (2023) indicated that 2-Chloro-5-cyclopropylpyridine itself shows low acute toxicity (LD50 > 2000 mg/kg in rodent models), though some derivatives with specific substitutions displayed hepatotoxicity at higher doses. These findings emphasize the importance of careful structural modification in drug development programs utilizing this scaffold.

Looking forward, several pharmaceutical companies have included 2-Chloro-5-cyclopropylpyridine derivatives in their preclinical pipelines. Patent applications filed in 2023-2024 reveal its incorporation in candidates targeting inflammatory diseases, oncology, and central nervous system disorders. The compound's versatility and the growing body of research supporting its applications suggest it will remain an important tool in medicinal chemistry for the foreseeable future.

• 1409964-40-4(1-Chloro-4-cyclopropylisoquinoline)
• 68700-93-6(2-chloro-5-isopropylpyridine)
• 136117-94-7(5-Butyl-2-chloropyridine)
• 104801-39-0(2-Chloro-5-ethylpyridine hydrochloride)
• 90196-32-0(2-Chloro-5-ethylpyridine)
• 152211-49-9(Pyridine, 2-chloro-5-(triphenylmethyl)-)
• 1211529-21-3(2,6-Dichloro-3-cyclopropylpyridine)
• 64063-61-2(Pyridine, 2-chloro-5-(diphenylmethyl)-)
• 865664-04-6(2-Chloro-3-cyclopropylpyridine)
• 854267-89-3(1-(6-Chloropyridin-3-yl)cyclopropanecarbonitrile)